TY - JOUR
T1 - Hyperhomocysteinemia in ankylosing spondylitis
T2 - Prevalence and association with clinical variables
AU - Gonzalez-Lopez, Laura
AU - Sanchez-Hernandez, Julia D.
AU - Aguilar-Chavez, Erika A.G.
AU - Cota-Sanchez, Adolfo R.
AU - Lopez-Olivo, Maria A.
AU - Villa-Manzano, Alberto I.
AU - Ortega-Flores, Ricardo
AU - Espinoza-Magaña, Genadia L.
AU - Rojo-Contreras, Wendoline
AU - Cardona-Muñoz, Ernesto G.
AU - Gamez-Nava, Jorge I.
N1 - Funding Information:
Acknowledgment This work was supported by the Mexican Institute for Social Security (Instituto Mexicano del Seguro Social).
PY - 2008/10
Y1 - 2008/10
N2 - We evaluated the prevalence and characteristics associated with hyperhomocysteinemia in ankylosing spondylitis (AS). Ninety-seven patients with AS were compared with 97 controls. The assessment included clinical characteristics, disease activity (BASDAI), functioning (BASFI), history of drugs, and erythrocyte sedimentation rate (ESR). Total serum homocysteine (tHcy) was determined by fluorescence polarization immunoassay. A higher frequency of hyperhomocysteinemia (>15 μmol/L) was observed in AS (12 vs. 1%, P = 0.002). In the multivariate analysis the risk for hyperhomocysteinemia was increased in patients with higher score of HAQ-S (OR = 5.27, 95% CI: 1.29-21.44) and higher ESR (OR = 1.09, 95% CI: 1.02-1.18). No statistical associations was observed between hyperhomocysteinemia with other variables including methotrexate or sulfasalazine utilization. In conclusion, this study found a significant prevalence of hyperhomocysteinemia in Mexican patients with AS mainly associated to a worst functional impairment. Further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients.
AB - We evaluated the prevalence and characteristics associated with hyperhomocysteinemia in ankylosing spondylitis (AS). Ninety-seven patients with AS were compared with 97 controls. The assessment included clinical characteristics, disease activity (BASDAI), functioning (BASFI), history of drugs, and erythrocyte sedimentation rate (ESR). Total serum homocysteine (tHcy) was determined by fluorescence polarization immunoassay. A higher frequency of hyperhomocysteinemia (>15 μmol/L) was observed in AS (12 vs. 1%, P = 0.002). In the multivariate analysis the risk for hyperhomocysteinemia was increased in patients with higher score of HAQ-S (OR = 5.27, 95% CI: 1.29-21.44) and higher ESR (OR = 1.09, 95% CI: 1.02-1.18). No statistical associations was observed between hyperhomocysteinemia with other variables including methotrexate or sulfasalazine utilization. In conclusion, this study found a significant prevalence of hyperhomocysteinemia in Mexican patients with AS mainly associated to a worst functional impairment. Further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients.
KW - Ankylosing spondylitis
KW - BASFI
KW - Hyperhomocysteinemia
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=51649102976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51649102976&partnerID=8YFLogxK
U2 - 10.1007/s00296-008-0687-4
DO - 10.1007/s00296-008-0687-4
M3 - Article
C2 - 18719918
AN - SCOPUS:51649102976
SN - 0172-8172
VL - 28
SP - 1223
EP - 1228
JO - Rheumatology International
JF - Rheumatology International
IS - 12
ER -